Related Suggestion
Omicron Has Put Many Countries' Coronavirus Sequencing Efforts to the Test
Omicron variant has shown surging cases in nearly 77 countries around the world in less than one month and seems to become a predominant variant in some regions.
WHO has officially appealed to countries that they must enhance surveillance & sequencing efforts to curb Omicron. Even in the developed countries, the sequencing capability is not satisfying, let alone say how insufficient in the developing countries with fragile health system. There are about 90000 daily cases in USA, but the sequencing capability is only around 18000, according to the CNN news. In France, before sequencing the virus of a suspected Omicron case, there will be a thorough tracking and quarantine to minimize the risk of transmission.
Rapid Antigen Test Considered Indispensable on Mass Screening
Facing the potential high transmissibility, it is quite urgent to implement mass screening in a fast and accurate way to avoid “hyperlocal outbreaks”, while rapid antigen test is considered indispensable and effective. Obviously, there's an urgent need to rather ramp up sequencing capability or figuring out a rapid way to identify Omicron variant for improving the situation. The new screening scheme with lower cost and higher efficiency is an essential topic especially for the developing countries.
Fapon Biotech Developed POCT Test Solution to Identify SARS-CoV-2 Omicron within Half an Hour
As a mainstream COVID-19 testing raw
materials and reagent
solution supplier to global top-profile reagent
manufacturers, Fapon Biotech is racing to develop faster and more convenient
way to identify Omicron variant, introducing POCT Test Solution for SARS-CoV-2 and Its Omicron Variant
Identification. The new patented product can be used to quickly detect
the patients with SARS-CoV-2 infection and to identify the Omicron mutant
strains infection just in one test. Utilizing this, the screening process for
mutant strains could be greatly optimized. For one thing, the rapid antigen
test for Omicron could help quickly implemented test-trace-isolate strategies
and lockdowns. On the other hand, the additional POCT test can screen out some
infectious patients and reduce the pressure on PCR testing.
Product Principle（applied
for patent）：
Note:T1 line is for wild-type strain, T2 line is for Omicron. When color in T1 and faint color in T2, it is interpreted as infection of Omicron variant. When color in T1 and T2, it is interpreted as positive in COVID-19 but non-infection of Omicron.
For this newly developed patented POCT Test Solution for SARS-CoV-2 and Its
Omicron Variant Identification, Fapon Biotech has used recombinant N
protein for preliminary test, while further verification experiments on Omicron
live virus are entrusted with a remarkable research team.
Fapon
Biotech Proposes Wider Range Experiment by Providing Free Test Solution for
More Rapid Countermeasure on Omicron
Considering the satisfactory progress on
the internal experiment result, Cui Peng, Chairman of Fapon Biotech,
passionately said that Fapon will continue to optimize the verification method.
“Meanwhile, we’d like to propose a wider range experiment on this
new-product-based screening scheme, and joint development on the product,
inviting global manufactures, developers, and decision-makers from government
who are taking all the efforts to optimize the epidemic prevention policies in
different countries.” He added, “Fapon Biotech is pleased to donate FREE POCT Test Solution for SARS-CoV-2 and its
Omicron Variant Identification to support research for the screening scheme.
If the new scheme is verified to be highly promising in practice, Fapon is
willing to provide more free products for the implementation in different
countries.”
For those who are interested in the donation details, you are warmly welcome to contact Fapon Biotech for further information via email (market@fapon.com).
